Dermal Mycosis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Dermal Mycosis Epidemiology Forecast Report Coverage

Expert Market Research's “Dermal Mycosis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of dermal mycosis. It projects the future incidence and prevalence rates of dermal mycosis cases across various populations.  The study covers age, gender, and type as major determinants of the dermal mycosis population. The report highlights patterns in the prevalence of dermal mycosis over time and projects future trends based on multiple variables.

Dermal Mycosis Understanding: Disease Overview

Dermal mycosis refers to superficial fungal infections affecting the skin, hair, and nails, commonly caused by dermatophytes, candida species, and Malassezia, aligning with cutaneous fungal infection incidence patterns. These infections thrive in warm, humid environments and are highly prevalent worldwide. Clinical manifestations vary widely, ranging from erythematous scaly lesions to chronic nail dystrophy. Although not life-threatening, dermal mycoses contribute significantly to morbidity, recurrence, and healthcare burden globally.

Dermal Mycosis Epidemiology Perspective

The dermal mycosis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the dermal mycosis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for dermal mycosis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Dermal mycosis, including dermatophytosis, pityriasis versicolor, and cutaneous candidiasis, had a global prevalence of 616.5 million cases and 1,729.2 million new annual cases, reflecting a high global fungal infection burden across populations.
• Globally, males exhibit a slightly higher burden than females, indicating modest differences in incidence and healthcare utilization, highlighting sex-based infection distribution trends in fungal skin diseases.
• Age distribution shows that children aged 5-9 years have the highest prevalence and incidence, reflecting increased exposure and transmission, indicating pediatric fungal infection prevalence patterns globally.
• Black and Hispanic populations show higher rates of tinea versicolor, demonstrating disparities in diagnosis and outcomes, reflecting ethnic variation in skin infection rates.

Read more about this report - Request a Free Sample

Country-wise Dermal Mycosis Epidemiology

The dermal mycosis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Dermal mycoses exert a notable clinical burden across regions, reflecting distinct regional dermatophytosis prevalence patterns. In India, prevalence ranges from 6.1% to 27.6% in southern hospital settings and up to 61.5% in northern studies, with increasing chronic cases. In Japan, reported clinical data identified 9,442 dermatomycoses cases, predominantly dermatophytosis, followed by candidiasis and Malassezia infections, highlighting ongoing clinical challenges.

Dermal Mycosis: Treatment Overview

Management of dermal mycosis depends on infection severity, anatomical site, and causative organism, aligning with evolving antifungal treatment response trends. Topical antifungals remain first-line therapy, while oral agents are used for extensive or chronic infections. Treatment duration varies, especially for nail involvement. Adjunctive measures include hygiene improvement and avoidance of steroid misuse. Rising antifungal resistance has increased the need for culture-guided therapy in refractory cases.

Key Questions Answered

• What are the key findings of dermal mycosis epidemiology in the 8 major markets?
• What will be the total number of patients with dermal mycosis across the 8 major markets during the forecast period?
• What was the country-wise dermal mycosis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of dermal mycosis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of dermal mycosis during the forecast period of 2026-2035?
• What are the currently available treatments for dermal mycosis?
• What are the disease risks, signs, symptoms, and unmet needs of dermal mycosis?

Scope of the Dermal Mycosis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of dermal mycosis based on several factors.
• Dermal Mycosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The dermal mycosis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Onychomycosis Market Size

Onychomycosis Pipeline Analysis